Septerna, Inc. (SEPN) Stock Price & How to Invest

Last updated November 2026

Short answer

SEPN trades on the Nasdaq as ordinary common stock, so any US broker can buy it in whole or fractional amounts, and some small-cap biotech and Russell index funds hold it. Septerna is a clinical-stage drug developer with no approved product, so the case for it rests on three things: a Novo Nordisk partnership that is currently paying most of the bills, two clinical programs with readouts between late 2026 and 2027, and a cash pile large enough to fund the company into 2029. As of October 16, 2026 the shares closed at $36.22, up about 30% year to date and about 61% over one year, but roughly 29% below the 52-week high of $51.10 reached after second-quarter results.

SEPN stock price

As of 2026-11-16, Septerna, Inc. (SEPN) last closed at $41.67, up 92.6% over the past year. Over the past 52 weeks it has traded between $21.64 and $52.34.

SEPN last close
$41.67
1 day
-2.18%
1 month
+14.64%
1 year
+92.56%
52-week range
$21.64 to $52.34
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Septerna, Inc.'s investor relations page. Walnut is informational, not investment advice.

SEPN key stats

At $41.67 on November 16, 2026, Septerna, Inc. (SEPN) has a market cap of $1.9B.

Market cap
$1.9B
Price to book
4.6

Market cap, P/E and yield are measured at the $41.67 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Septerna, Inc. (SEPN)?

The last two weeks for Septerna, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • SEPN closed at $41.67 on November 16, 2026, down 17.9% over the past five trading days (from $50.74).
  • On November 9, 2026, Septerna, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 9, 2026, Septerna, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 4, 2026, Septerna, Inc. filed an 8-K with the SEC reporting information shared with investors (Regulation FD) (Item 7.01). Read the 8-K on sec.gov
  • On November 10, 2026, Stifel raised its target to $60.00 from $49.00 (Buy).
  • On November 6, 2026, Guggenheim raised its target to $65.00 from $51.00 (Buy).
  • On November 4, 2026, Wells Fargo raised its target to $61.00 from $50.00 (Overweight).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Septerna, Inc. (SEPN) latest quarter

Septerna reported revenue of $18.9 million for Q3 2026, down 12% from a year earlier (Septerna, Nov 9, 2026).

Revenue
$18.9 million
down 12% from a year earlier
Diluted EPS
-$0.57
n/a
Net income
-$26.6 million
n/a

Source: Septerna Q3 2026 results, Nov 9, 2026. Full earnings breakdown

What does Septerna, Inc. (SEPN) do?

Septerna, Inc. designs oral small molecule drugs against G protein-coupled receptors, the receptor family that sits behind roughly a third of approved medicines but which has historically been drugged with injectables or with molecules found by luck rather than by design. Its Native Complex Platform reconstitutes GPCRs outside the cell in a form stable enough to screen and to solve structurally, which is what lets the company go after targets that are usually reached with peptides or antibodies. Three efforts define the pipeline in 2026: SEP-631, an oral MRGPRX2 antagonist aimed at chronic spontaneous urticaria; SEP-479, a next-generation oral PTH1R agonist for hypoparathyroidism; and a global collaboration with Novo Nordisk on oral GPCR programs in obesity, type 2 diabetes and other cardiometabolic disease. The company listed on the Nasdaq in October 2024 with an upsized IPO that raised about $288 million.

The financial shape is unusual for a company at this stage. Trailing twelve-month revenue is roughly $99 million, essentially all of it collaboration revenue recognized from the Novo Nordisk agreement rather than product sales, and that inflow has held the trailing net loss to about $24 million against a cash balance near $516 million. Management guides that cash into 2029, which is a long horizon by clinical-stage standards and removes the near-term financing pressure that usually dictates when these companies raise. What the market is pricing at a roughly $1.7 billion capitalization (October 16, 2026) is the pipeline, not the revenue line. The stock has moved accordingly: it closed around $47.76 on August 11, 2026 after a 23% single-day move around second-quarter results and a round of analyst target increases, went on to a 52-week high of $51.10, and then gave back much of that to close at $36.22 on October 16, 2026, still up about 30% year to date, and carries the memory of February 2025, when the discontinuation of the original PTH1R candidate SEP-786 cut the share price 47% in one session. In late August 2026 the company appointed Rajiv Patni, M.D., as chief medical officer ahead of the SEP-631 Phase 2b and the SEP-479 readout. Third-quarter results are expected around November 9, 2026 (an estimated date), with consensus revenue near $20.8 million, below the recent run rate.

What's driving Septerna, Inc. (SEPN)?

1. The Novo Nordisk collaboration

The partnership covers oral small molecule programs against specified GPCR targets in obesity, type 2 diabetes and related cardiometabolic disease, and it is the source of nearly all reported revenue. Second-quarter 2026 revenue of about $26.8 million came in ahead of the roughly $19.2 million analysts expected, and the quarterly run rate has been steady near that level since the deal began contributing. This is research and milestone revenue recognized under an accounting schedule, so it should be read as validation and funding rather than as a commercial business, and it can slow or stop if programs are not advanced. Consensus expects the line to ease, to about $20.8 million in the third quarter and about $74 million for 2027 versus about $96 million in 2026.

2. SEP-631 into Phase 2b

SEP-631 is an oral MRGPRX2 antagonist for chronic spontaneous urticaria, a condition currently treated with antihistamines and then with injected biologics such as omalizumab. Phase 1 data showed clinical proof of mechanism and cleared the program to move into Phase 2b in the second half of 2026. An oral option in a market that otherwise means regular injections is the commercial argument, and the Phase 2b design and enrollment pace are the near-term things to follow.

3. SEP-479 and the second attempt at oral hypoparathyroidism

SEP-479 is a next-generation oral PTH1R agonist that replaced SEP-786 after that candidate was halted on unexpected bilirubin elevations in 2025. Phase 1 started in the first half of 2026 and data is expected in early 2027, with Stifel and Guggenheim both raising targets in August 2026 partly on the human half-life profile disclosed so far. Because the safety issue that ended the earlier program sat in the same target class, the tolerability portion of that readout carries more weight than a typical Phase 1.

4. Funding depth

Cash and investments stood at roughly $516.5 million at the end of June 2026 (Yahoo Finance shows about $372 million of that as cash, with debt of only about $23 million), guided to fund operations at least into 2029. Collaboration revenue is covering a large share of the burn, which is why the trailing net loss is around $24 million rather than the $100 million-plus a company running two clinical programs would normally post. A runway that long means the company can, in principle, reach several readouts without raising, though biotechs with strong data frequently raise anyway when the window is open.

What are the risks to Septerna, Inc. (SEPN)?

Every clinical-stage biotech carries binary risk, and here it has already been demonstrated: SEP-786 was discontinued in February 2025 after two severe cases of elevated unconjugated bilirubin, and the stock fell 47% that day. Several plaintiffs' firms announced investigations in the weeks after, which is a routine response to a drop of that size and did not produce a widely reported class action, but the episode is the clearest illustration of how this name trades on single data points. Revenue is collaboration accounting rather than product sales, so it is not a floor under the valuation, and Novo Nordisk can deprioritize programs. With roughly 46.7 million shares outstanding the float is small and daily moves of 20% in either direction are ordinary. Both target markets are contested, hypoparathyroidism by Ascendis and AstraZeneca with approved or late-stage injectables and chronic spontaneous urticaria by several biologics and oral candidates, so positive data still has to clear a commercial bar rather than an empty field. The fall from about $51 to $36.22 between August and mid-October 2026, with no adverse company news in that stretch, shows how far sentiment alone can move the shares. Analysts also expect losses to widen, to about $1.94 a share in 2027 as collaboration revenue is forecast to decline.

What is the Septerna, Inc. (SEPN) forecast?

9 analysts publish price targets on SEPN, averaging $56.78 as of November 2026, or +36.3% against the $41.67 share price on November 16, 2026. The published targets run from $48.00 to $65.00, a narrow spread, and the ratings split 10 buy, 0 hold, 0 sell. Over the last six months there have been 10 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full SEPN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is SEPN a buy or a sell?

We give no verdict on Septerna, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The Novo Nordisk collaboration. The partnership covers oral small molecule programs against specified GPCR targets in obesity, type 2 diabetes and related cardiometabolic disease, and it is the source of nearly all reported revenue. The most optimistic published target, $65.00, assumes this works close to its best case.

The case against. Every clinical-stage biotech carries binary risk, and here it has already been demonstrated: SEP-786 was discontinued in February 2025 after two severe cases of elevated unconjugated bilirubin, and the stock fell 47% that day. The most pessimistic target, $48.00, is roughly what SEPN is worth if this bites instead.

Read the full bull and bear case on SEPN, including what would have to change to break either one. Walnut is not an investment adviser.

Has Septerna, Inc. (SEPN) split its stock?

No. Septerna, Inc. (SEPN) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Septerna, Inc. (SEPN) valued?

Market cap, P/E and dividend yield at today's price are in the SEPN key stats above. The business figures below come from Septerna, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$99 million, essentially all collaboration revenue from Novo Nordisk rather than product sales
  • Revenue (Q2 2026): ~$26.8 million versus consensus near $19.2 million
  • Net loss: ~$24 million TTM (~$0.54 per share); Q2 2026 ~$13 million, EPS -$0.29 vs -$0.49 consensus
  • Cash: ~$516.5 million cash and investments at June 30, 2026, guided to fund operations at least into 2029
  • 52-week range: ~$17.55 to ~$51.10

As of October 2026: Price to sales of roughly 17 times shows up on screeners, but the denominator is partnership revenue on a recognition schedule, so the ratio does not describe a commercial business and comparing it to a specialty pharma multiple is not meaningful. The more useful framing is enterprise value: about $1.7 billion of market cap against roughly $516 million of cash and investments leaves close to $1.2 billion attributed to a pipeline whose most advanced asset is entering Phase 2b, down from about $1.7 billion in August. The nine-analyst mean target is about $54, well above the October 16, 2026 close of $36.22, and the next report is expected around November 9, 2026.

Who competes with Septerna, Inc. (SEPN)?

GPCR-focused oral small molecule biotechs

Structure Therapeutics is the closest platform comparison, using structure-based design to build oral small molecules against GPCRs, with its lead work in obesity. Viking Therapeutics and Terns Pharmaceuticals compete for the same investor attention around oral metabolic drugs. These companies compete less for patients today than for capital, talent and partnership deals with large pharma, which is where Septerna's Novo Nordisk agreement gives it an edge that the others have to match.

Hypoparathyroidism treatments

Ascendis Pharma markets Yorvipath, a once-daily injected PTH replacement, and AstraZeneca acquired Amolyt Pharma for eneboparatide in the same indication. Both are injectables, which is precisely the gap SEP-479 is designed to fill, so the question for Septerna is whether an oral option with comparable calcium control can take share from established injections. Standard of care for patients not on these drugs remains calcium and active vitamin D supplementation.

Chronic spontaneous urticaria treatments

Omalizumab (Xolair) from Genentech and Novartis is the entrenched biologic, dupilumab from Regeneron and Sanofi has expanded into the indication, and Celldex's barzolvolimab plus Novartis's oral remibrutinib are the closest late-stage challengers. SEP-631 enters a field where the bar is set by injectables with years of data, so an oral pill has to show enough efficacy to justify the switch rather than merely being more convenient.

What stocks are similar to Septerna, Inc. (SEPN)?

Other names that sit close to SEPN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Septerna, Inc. (SEPN)

There are three common ways to get SEPN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SEPN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SEPN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Septerna, Inc. (SEPN)

Septerna is a funded, partnered, pre-commercial biotech whose share price is a running bet on clinical data, and the 2025 discontinuation of its original lead program is the reason that bet has to be sized carefully.

More on Septerna, Inc. (SEPN)

Whether SEPN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SEPN a buy or a sell?, and where the stock could go from here in the SEPN stock forecast.

For income investors, whether SEPN pays a dividend and how the payout looks is covered in does SEPN pay a dividend? And to weigh SEPN against a peer, read the full side-by-side comparisons: SEPN vs VKTX and SEPN vs NVO.

Wondering how SEPN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Septerna, Inc.

Ask Walnut's AI anything about SEPN and see how it fits what you own.

FAQ

What does Septerna actually do?

+

It discovers and develops oral small molecule drugs aimed at G protein-coupled receptors, a receptor family involved in a very large share of human biology. Its Native Complex Platform stabilizes those receptors outside the cell so they can be screened and structurally resolved, which is the technical basis for going after targets normally addressed with injected peptides or antibodies. The company is clinical stage, meaning it is running trials and has not yet sold a drug.

Where does Septerna's revenue come from if it has no approved drug?

+

Almost entirely from its global collaboration with Novo Nordisk on oral GPCR programs in obesity, type 2 diabetes and other cardiometabolic disease. Upfront and research milestone payments are recognized as revenue over time, which produced about $26.8 million in the second quarter of 2026 and roughly $99 million over the trailing year. It is partnership money, not product sales, and it stops if the underlying research programs stop.

How does a US investor buy SEPN?

+

SEPN is ordinary common stock listed on the Nasdaq, so any US broker can trade it in dollars during normal market hours, including fractionally at brokers that support fractional shares. It is also held by small-cap and biotech index funds and by actively managed healthcare funds, which is the indirect route for anyone who would rather not hold a single pre-revenue drug developer.

Why did SEPN jump in August 2026?

+

The shares rose about 23% on August 11, 2026, closing near $47.76. Second-quarter revenue of roughly $26.8 million beat the consensus near $19.2 million, and Guggenheim raised its target to $51 while Stifel went to $49, both citing pipeline progress and the human half-life data emerging from the SEP-479 program. The stock had already roughly tripled over the prior twelve months from a low near $10.62. The shares later peaked at a 52-week high of $51.10 before easing back to $36.22 by October 16, 2026.

What happened with SEP-786 in 2025?

+

SEP-786 was Septerna's original oral PTH1R agonist for hypoparathyroidism. In February 2025 the company discontinued its Phase 1 trial after two unexpected severe cases of elevated unconjugated bilirubin, notably without matching liver enzyme increases, and the stock fell about 47% in a single session. Several plaintiffs' law firms announced investigations in the following weeks, a common reaction to a drop of that magnitude. SEP-479 is the next-generation candidate that replaced it.

What is SEP-631 and why does it matter?

+

SEP-631 is an oral MRGPRX2 antagonist being developed for chronic spontaneous urticaria, a chronic hives condition where patients who fail antihistamines usually move to injected biologics. Phase 1 results established clinical proof of mechanism and supported a move into Phase 2b in the second half of 2026. It is the most advanced wholly owned program, so its Phase 2b outcome is the largest single swing factor in the pipeline over the next two years.

How long can Septerna fund itself?

+

Cash was roughly $516.5 million at the end of June 2026 and management guides that it funds operations at least into 2029. Collaboration revenue offsets a meaningful share of the burn, which is why the trailing net loss is near $24 million rather than the far larger figure a two-program clinical developer would normally report. A long runway reduces forced-financing risk, though companies in this position often still raise opportunistically after good data.

Does Septerna pay a dividend?

+

No. Septerna is a pre-commercial biotech that reinvests everything into research and clinical development, and there is no dividend or buyback. Total return from the shares comes only from price movement, which for this name has meant a 47% single-day drop in 2025 a roughly threefold gain over the year to August 2026, and a slide of about 29% from the August peak by mid-October 2026.

How did Septerna do in its latest quarter?

+

In the second quarter of 2026, Septerna reported collaboration revenue of about $26.8 million, ahead of the roughly $19.2 million consensus, and a net loss of about $13 million, or $0.29 a share against an expected $0.49 loss. Cash and investments were about $516.5 million at June 30, 2026. Third-quarter results are expected around November 9, 2026, with analysts looking for revenue near $20.8 million and a loss of about $0.40 a share.

How has SEPN stock performed in 2026?

+

As of the October 16, 2026 close of $36.22, SEPN was up about 30% year to date and about 61% over one year, after peaking at $51.10 following the August results. Over the past month it fell about 6%. Walnut is not an investment adviser, and a clinical-stage biotech's past moves say little about its next data readout.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Septerna, Inc.'s investor relations page or your broker before making investment decisions.